Dr. Christiaan Schiepers is interested in multi-modality imaging in diagnostic oncology, with F-18 and C-11 labeled probes. The specific probes utilized are FDG, FLT, FDOPA, FAC, acetate and fluoride. Kinetic models for probes in humans were developed for FLT and FDOPA in glioma, Acetate in prostate cancer, and Fluoride in osteoporosis, Paget’s disease and osseous metastases. He has investigated and published dosimetry of a new family of FAC-probes in humans.
Selected Cancer-Related Publications:
Wardak M, Schiepers C, Dahlbom M, Cloughesy T, Chen W, Satyamurthy N, Czernin J, Phelps ME, Huang SC. Discriminant analysis of ??F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clin Cancer Res. 2011 Oct 15;17(20):6553-62. Epub 2011 Aug 25
Schiepers C, Dahlbom M. Molecular imaging in oncology: the acceptance of PET/CT and the emergence of MR/PET imaging. Eur Radiol. 2011 Mar;21(3):548-54. Epub 2010 Dec 21
Schwarzenberg J, Radu CG, Benz M, Fueger B, Tran AQ, Phelps ME, Witte ON, Satyamurthy N, Czernin J, Schiepers C. Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway. Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):711-21. Epub 2010 Dec 3
Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME, Huang SC. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med. 2010 May;51(5):720-7. doi: 10.2967/jnumed.109.068361. Epub 2010 Apr 15.
Schiepers C, Hoh CK, Nuyts J, Seltzer M, Wu C, Huang SC, Dahlbom M. 1-11C-acetate kinetics of prostate cancer. J Nucl Med. 2008 Feb;49(2):206-15. doi: 10.2967/jnumed.107.044453. Epub 2008 Jan 16.